Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value drivers as well as de-...

Related Keywords

Washington ,United States ,South San Francisco ,California ,Seattle ,Fred Hutch ,Lynn Seely ,Ellen Rose ,Tina Albertson ,Nasdaq ,Exchange Commission ,Development Expenses ,Lyell Immunopharma Inc ,Fred Hutchinson Cancer Center ,Chief Medical Officer ,Quarter Updates ,Recent Business ,Chimeric Antigen Receptor ,Cellare Cell Shuttle ,Annual Meeting ,San Diego ,Lyell Immunopharma ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Operations Data ,Months Ended September ,Condensed Consolidated Statements ,Sheet Data ,Vice President ,